TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, today announced that it has appointed Gail O’Brien Turner as Vice President, Sales.
Ms. Turner brings to TYRX over 25 years of sales and management experience in the medical device space through her numerous positions of increasing responsibility with Guidant, now part of Boston Scientific. Most recently, Ms. Turner held the role of Area Vice President of Sales, CRMD, where she had responsibility for the Northeast and managed 135 field personnel and was accountable for revenue of $300 million. Ms. Turner began her career with IVAC, successfully selling infusion devices and vital signs monitoring equipment, and then moved to the Interventional Cardiology market (ACS), where she was equally successful in selling angioplasty catheters and launching the Multi-Link Stent. Her last role within Guidant was to manage the Leadership Development effort across all business units, where she was responsible for identifying and developing key managerial talent for the organization. Ms. Turner has been recognized and named “Rising Star” by the Healthcare Businesswoman Association, a national award that recognizes achievement and excellence in leadership. Ms. Turner earned a BS degree in Economics from Boston College.
“Gail brings to TYRX a unique blend of sales skills, sales management experience, and personnel development,” remarked William Edelman, President and CEO for TYRX. Mr. Edelman continued, “Gail’s experience in the Cardiac Rhythm Management space, as well as her demonstrated track record of leading successful sales organizations, will contribute greatly to the ongoing commercialization of the AIGISRx Anti-Bacterial Envelope in the implantable medical device market.”
Ms. Turner remarked, “I am thrilled to be at TYRX. I view this as a tremendous opportunity, in light of the increasing awareness and impact of surgery acquired infections related to device implants. It is my belief that the AIGISRx product is the most effective approach in reducing these life threatening and costly complications. It will set a new standard in patient care.”
Source: TYRX, Inc.
published: March 4, 2009 in: Companies, News, People, Products